“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.

The NRG-GU011 trial evaluates relugolix plus SBRT versus SBRT alone in men with PSA recurrence and PSMA-PET-detected metastases. The study addresses whether targeted radiation can delay hormone ...

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that ...

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that ...

UGN-102's NDA acceptance marks a potential first FDA-approved treatment for LG-IR-NMIBC, with a PDUFA date of June 13, 2025. The phase 3 ENVISION trial demonstrated a 79.6% complete response rate at 3 ...

"We found that as soon as we got to the range of biochemical recurrence-defined PSA—0.2 ng/mL and up—the detection rate was very high," says Bridget Koontz, MD, FASTRO.

PSMA-PET imaging enables molecular-level detection of prostate cancer cells, often before CT or MRI abnormalities are visible. Sensitivity of PSMA-PET/CT in recurrent prostate cancer can reach 97% ...

Oliver Sartor, MD, discusses how a 70-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) represents a typical candidate for PSMA-targeted imaging and potential ...

According to iota Biosciences, the device is “designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals impacted by ...

Simultaneous F rhPSMA-7.3 PET/MRI imaging demonstrated a 93.75% PPV in detecting recurrent prostate cancer lesions. The study involved 29 patients, with 79% experiencing changes in radiation therapy ...

The application is supported by data from the pivotal phase 3 ARANOTE trial. Bayer has submitted an application to the European Medicines Agency (EMA) seeking approval of darolutamide (Nubeqa) in ...

Active surveillance is effective for low-risk prostate cancer, with low metastasis and mortality rates over 10 years. The study underscores the need for improved risk stratification to minimize ...